Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules

Blood

Volumn 95, Issue 2, 2000, Pages 564-568

  Barrow, Rachel T ^b   Healey, John F ^b   Gailani, David ^b   Scandella, Dorothea ^b   Lollar, Pete ^a  

^a EMORY UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; IMMUNOGLOBULIN LIGHT CHAIN;

ANIMAL CELL; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; SEQUENCE ANALYSIS;

EID: 0034651022     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.564     Document Type: Article

References (36)

1. Hoyer LW, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin Hematol. 1994;31:1-5.
2. Scandella D, Kessler C, Esmon P, et al. Epitope specificity and functional characterization of factor VIII inhibitors. Adv Exp Med Biol. 1995;386: 47-63.
3. Scandella D. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sang. 1996;70(suppl 1):9-14.
4. Lollar P. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Thromb Haemost. 1997;78:647-651.
5. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337-342.
6. Fass DN, Knutson GJ, Katzmann JA. Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood. 1982;59:594-600.
7. Lollar P, Parker CG. Subunit structure of thrombin-activated porcine factor VIII. Biochemistry. 1989;28:666-674.
8. Curtis JE, Helgerson SL, Parker ET, Lollar P. Isolation and characterization of thrombin-activated human factor VIII. J Biol Chem. 1994;269:6246-6251.
9. Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem. 1995;270:14,505-14,509.
10. Lollar P, Parker ET, Curtis JE, et al. Inhibition of human factor Villa by anti-A2 subunit antibodies. J Clin Invest. 1994;93:2497-2504.
11. Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood. 1998;92:3701-3709.
12. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248-2312 which overlap a phospholipid binding site. Blood. 1995;86:1811-1819.
13. Arai M, Scandella D, Hoyer LW. Molecular basis of factor-VIII inhibition by human antibodies: antibodies that bind to the factor-VIII light chain prevent the interaction of factor-VIII with phospholipid. J Clin Invest. 1989;83:1978-1984.
14. Fijnvandraat K, Celie PHN, Turenhout EAM, et al. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood. 1998;91:2347-2352.
15. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VMI binding to factor IX. Blood. 1998;92:136-142.
16. Prescott R, Nakai H, Saenko EL, et al. The inhibitory antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with fVIII autoantibodies. Blood. 1997;89:3663-3671.
17. Morrison AE, Ludlam CA, Kassler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993;81:1513-1520.
18. Fiks-Sigaud M, Bendelac L, Parquet A, et al. Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe hemophilia A. Vox Sang. 1993;64:210-214.
19. Lloyd JV, Street AM, Berry E, et al. Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand. Aust N Z J Med. 1997;27:658-664.
20. Lubin IM, Healey JF, Scandella D, Runge MS, Lollar P. Elimination of a major inhibitor epitope in factor VIII. J Biol Chem. 1994;269:8639-8641.
21. Ho SN, Hunt HD, Norton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77:51-59.
22. Bowie EJW, Owen CA. The clinical and laboratory diagnosis of hemorrhagic disorders. In Ratnoff OD, Forbes CD, eds. Disorders of Hemostasis. Orlando: Grune & Stratton: 1984:43.
23. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:612.
24. Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost. 1992;67:665-671.
25. Lubin IM, Healey JF, Scandella D, Lollar P: Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem. 1997;272:30,191-30,195.
26. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem. 1996;271:1935-1940.
27. Lenting PJ, Donath MSH, van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIM. J Biol Chem. 1994;269:7150-7155.
28. Fulcher CA, Roberts JR, Holland LZ, Zimmerman TS. Human factor VIII procoagulant protein: monoclonal antibodies define precursor-product relationships and functional epitopes. J Clin Invest. 1985;76:117-124.
29. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988;263:10,451-10,455.
30. Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem. 1990;265: 17,854-17,858.
31. Hill-Eubanks DC, Parker CG, Lollar P. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sci USA. 1989;86:6508-6512.
32. Kernoff PBA. Porcine factor VIII: preparation and use in treatment of inhibitor patients. In Hoyer LW, ed. Factor VIII Inhibitors. New York: Alan R. Liss: 1984:207.
33. Brettler DM. inhibitors in congenital haemophilia. Baillieres Clin Haematol. 1996;9:319-329.
34. Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol. 1996;9:331-354.
35. Koshihara K, Qian J, Lollar P, Hoyer LW. Immunoblot crossreactivity of factor VIII inhibitors with porcine factor VIII. Blood.1995; 86:2183-2190.
36. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312:330-337.